SNTI

Senti Biosciences Inc

Add to Watchlist

Advanced Chart

1.580

+0.04(2.597%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.6186

Open

1.570

VWAP

1.57

Vol

89.14K

Mkt Cap

41.33M

Low

1.550

Amount

140.24K

EV/EBITDA(TTM)

Total Shares

45.76M

19.76M

EV/OCF(TTM)

P/S(TTM)

Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

0.00

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Senti Biosciences, Inc. (SNTI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -51.53%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-26.88%

In Past 3 Month

Stock Price

Go Down

-51.53%

In Past 3 Month

1 Analyst Rating

216.46% Upside

Wall Street analysts forecast SNTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNTI is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

216.46% Upside

Current: 1.580

Low

5.00

Averages

5.00

High

5.00

216.46% Upside

Current: 1.580

Low

5.00

Averages

5.00

High

5.00

Laidlaw

NULL -> Buy

initiated

2025-06-06

Reason

Laidlaw

Price Target

2025-06-06

initiated

NULL -> Buy

Reason

Laidlaw initiated coverage of Senti Bio with a Buy rating and $5 price target. Senti is an early clinical stage oncology-emphasized biotech company that focuses on a novel and differentiated CAR-NK therapy, SENTI-202, as a potential high-risk relapsed or refractory acute myeloid leukemia treatment, the analyst tells investors in a research note. The firm says the company recently reported "very promising" Phase I interim results.

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$10 → $12

2024-12-04

Reason

Chardan Capital

Geulah Livshits

Price Target

$10 → $12

2024-12-04

Maintains

Strong Buy

Reason

Chardan analyst Geulah Livshits raised the firm's price target on Senti Bio to $12 from $10 and keeps a Buy rating on the shares after the company reported data and hosted a call to discuss initial results from the Phase 1 trial of its donor-derived logic-gated CARNK SENTI-202 in relapsed/refractory hematologic malignancies. Having "digested the data in a bit more detail," the firm increased its view of the probability of success for SENTI-202 to 35% from 25%, the analyst tells investors.

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$10

2024-12-02

Reason

Chardan Capital

Geulah Livshits

Price Target

$10

2024-12-02

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Senti Biosciences Inc (SNTI.O) is -0.54, compared to its 5-year average forward P/E of -1.12. For a more detailed relative valuation and DCF analysis to assess Senti Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.12

Current PE

-0.54

Overvalued PE

0.35

Undervalued PE

-2.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.80

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.98

Undervalued EV/EBITDA

-2.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.66

Current PS

23.02

Overvalued PS

35.71

Undervalued PS

-4.39

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

+25.77%

-16.80M

Operating Profit

FY2025Q2

YoY :

+31.51%

-14.73M

Net Income after Tax

FY2025Q2

YoY :

-97.71%

-0.56

EPS - Diluted

FY2025Q2

YoY :

+59.01%

-13.27M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

24.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

24.4K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SNTI News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

08:10:47

Senti Bio reports Q2 EPS (56c) vs. ($2.45) last year

2025-08-05 (ET)

2025-08-05

08:46:42

Senti Bio confirms recommended RP2D in Phase 1 study of SENTI-202

2025-07-18 (ET)

2025-07-18

08:57:40

Senti Bio appoints Bryan Baum to board of directors

News

4.0

08-08Benzinga

Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target

9.5

08-07Newsfilter

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

1.0

07-21Newsfilter

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum